Skip to main content
SpringerLink
Log in

Comparison of the effectiveness of two mumps vaccines during an outbreak in Switzerland in 1999 and 2000: A case–cohort study

  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

Abstract

In two recent nation-wide outbreaks of mumps in Switzerland two-thirds of young children with clinical mumps had a history of primary vaccination. On average, measles–mumps–rubella (MMR) vaccination coverage is 80%. Two types of vaccine are commonly used: Jeryl-Lynn and Rubini. The effectiveness of the latter has been questioned in several publications. The authors therefore compared Rubini to Jeryl-Lynn in a case–cohort study. The study included 111 young children with clinical mumps who had been reported to the Swiss Federal Office of Public Health (SFOPH) by primary care physicians of the Swiss Sentinel Surveillance Network (SSSN) between January 1999 and May 2000. Sentinel physicians also sampled 661 children from the same birth cohort as the cases. While we found no evidence for the effectiveness of the Rubini strain, vaccination with the Jeryl-Lynn strain was 70% effective against clinical mumps. Furthermore, children vaccinated with the Rubini strain attended primary health care more frequently with clinical mumps than those who had received Jeryl-Lynn (odds ratio: 2.4; 95% confidence interval (CI): 1.3, 4.7). Restricting the analysis to laboratory confirmed cases increased the odds ratio to 18.4 (95% CI: 2.5, 811.2). Our study confirms the low effectiveness of the Rubini strain vaccine in the field. This vaccine should therefore be considered inappropriate for the control and elimination of mumps and its use should be discontinued. As other vaccines with comparable quality and safety standards and a substantially higher effectiveness are available the MMR vaccination program in Switzerland will not be compromised if the use of Rubini is no longer recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Matter HC, Cloetta J, Zimmermann H. Das Meldesystem Sentinella in der Schweiz am Beispiel des Pertussismonitorings von 1991 bis 1993. Schweizerische Rundschau für Medizin (PRAXIS) 1995; 84: 690–697.

    Google Scholar 

  2. Bundesamt für Gesundheit. Mumps 1995. Bulletin BAG/OFSP 1997; 16: 9–12.

    Google Scholar 

  3. Matter HC, Cloetta J, Zimmermann H, Sentinella Arbeitsgemeinschaft. Measles, mumps, and rubella: Monitoring in Switzerland through a sentinel network, 1986-1994. J Epidemiol Commun Health 1995; 49(Suppl 1): 4–8.

    Google Scholar 

  4. Bundesamt für Gesundheit. Erneute Zunahme der Mumpsfälle in der Schweiz. Bulletin BAG/OFSP 2000; 1: 4–7.

    Google Scholar 

  5. Somaini B. Ziele des Masern/Mumps/Rötelnimpfprogramms. Bulletin BAG/OFSP 1988; 3: 31–35.

    Google Scholar 

  6. Bundesamt für Gesundheit, Schweizerische Kommission für Impffragen. Impfplan für routinemässige Schutzimpfungen. In: Bundesamt für Gesundheit (ed.), Infektionskrankheiten: Diagnose und Bekämpfung. Bern: Bundesamt für Gesundheit, 1996; 1–5.

    Google Scholar 

  7. Bundesamt für Gesundheit, Schweizerische Kommission für Impffragen. Impfplan für routinemässige Schutzimpfungen. In: Bundesamt für Gesundheit (ed.), Infektionskrankheiten: Diagnose und Bekämpfung. Bern: Bundesamt für Gesundheit, 2001; 1–6.

    Google Scholar 

  8. Minder C, Steffen R. Kleinkinderimpfungen. Eine repräsentative Erhebung zur Durchimpfung in der Schweiz 1991. Bulletin BAG/OFSP 1992; 32: 504–507.

    Google Scholar 

  9. Bundesamt für Gesundheit. Kleinkinderimpfungen. Repräsentative Erhebung zur Durchimpfung in der Schweiz 1998. Bulletin BAG/OFSP 1999; 20: 356–361.

    Google Scholar 

  10. Paccaud MF, Hazeghi P, Bourquin M, et al. Rückblick auf zwei Mumpsausbrüche. Soz Praventivmed 1995; 40: 72–79.

    Google Scholar 

  11. Zimmermann HP, Matter HC, Kiener T, Sentinella Arbeitsgemeinschaft. Mumps-Epidemiologie in der Schweiz: Ergebnisse der Sentinella-Überwachung 1986-1993. Soz Praventivmed 1995; 40: 80–89.

    Google Scholar 

  12. Vaudaux B, Zimmermann HP, Bourquin C, Germann B. Effet protecteur du vaccin contre les oreillons (souche Rubini): étude du taux d'attaque secondaire. Présentation à la 88e Assemblée annuelle de la Société de Pédiatrie, Crans Montana, 22-24 juin 1995. Schweiz Med Wochenschr 1995; 125(Suppl 70): 6s.

  13. Toscani L, Batou M, Bouvier P, Schlaepfer A. Comparaison de l'efficacité de différentes souches de vaccin ourlien: Une enquête en milieu scolaire. Soz Präventivmed 1996; 41: 341–347.

    Google Scholar 

  14. Chamot E, Toscani L, Egger P, Germann D, Bourquin C. Estimation de l'efficacité de trois souches vaccinales ourliennes au cours d'une épidémie d'oreillons dans le canton de Genève. Rev Epidemiol Sante Publ 1998; 46: 100–107.

    Google Scholar 

  15. Gonçalves G, de Araùjo A, Cardoso MLM. Outbreak of mumps associated with poor vaccine efficacy - Oporto, Portugal, 1996. Eurosurveillance 1998; 3: 119–121.

    Google Scholar 

  16. Schlegel M, Osterwalder JJ, Galeazzi RL, Vernazza PL. Comparative efficacy of three mumps vaccines during disease outbreak in eastern Switzerland: Cohort study. Brit Med J 1999; 319: 352–353.

    Google Scholar 

  17. Goh KT. Resurgence of mumps in Singapore caused by the Rubini mumps virus vaccine strain. The Lancet 1999; 354: 1355–1356.

    Google Scholar 

  18. Pons C, Pelayo T, Pachòn I, et al. Two outbreaks of mumps in children vaccinated with the Rubini strain in Spain indicate low vaccine efficacy. Eurosurveillance 2000; 5: 80–84.

    Google Scholar 

  19. Germann D, Strohle A, Eggenberger K, Steiner CA, Matter L. An outbreak of mumps in a population partially vaccinated with the Rubini strain. Scand J Infect Dis 1996; 28: 235–238.

    Google Scholar 

  20. The Benevento and Compobasso Pediatricians Network for the Control of Vaccine-Preventable Diseases. Field evaluation of the clinical effectiveness of vaccines against pertussis, measles, rubella and mumps. Vaccine 1998; 16: 818–822.

    Google Scholar 

  21. De los Rios Martin R, Garcia Marin N, Sanz Morena JC, Ballester Orcal E. Parotiditis en un área urbana de la Comunidad de Madrid. Estado vacunal, diagnóstico y medidas de intervención. Atención Primaria 2001; 28: 10–16.

    Google Scholar 

  22. Moulton LH, Wolff MC, Brenneman G, Santosham M. Case-cohort analysis of case-coverage studies of vaccine effectiveness. Am J Epidemiol 1995; 142: 1000–1006.

    Google Scholar 

  23. Rothman KJ, Greenland S. Case-control studies. In: Rothman KJ, Greenland S (eds), Modern Epidemiology. Philadelphia, PA: Pippincott-Raven Publishers, 1998; 93–114.

    Google Scholar 

  24. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev 1988; 10: 212–241.

    Google Scholar 

  25. Miettinen O. Design options in epidemiologic research. An update. Scand J Work Environ Health 1982; 8: 7–14.

    Google Scholar 

  26. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. Morb Mortal Wkly Rep 1997; 46: RR-10–55.

    Google Scholar 

  27. Cheek JE, Baron R, Atlas H, Wilson DL, Crider RD. Mumps outbreak in a highly vaccinated school population. Evidence for large-scale vaccination failure. Arch Pediatr Adolesc Med 1995; 149: 774–778.

    Google Scholar 

  28. World Health Organization. Mumps virus vaccines: WHO position paper. Wkly Epidemiol Record 2001; 76: 346–355.

    Google Scholar 

  29. Bundesamt für Gesundheit. Nationales Impfprogramm: Mumpsimpfung. Das Bundes-amt für Gesundheit empfiehlt, Impfstoffe, die den Rubini-Stamm enthalten, wegen dessen geringer Wirksamkeit nicht mehr zu verwenden. Bulletin BAG/OFSP 2002; 16: 300–302.

    Google Scholar 

  30. World Health Organization, Expanded programme on immunization (EPI). Recrudescence of measles. Switzerland. Wkly Epidemiol Record 1998; 73: 137–139.

    Google Scholar 

  31. Paget WJ, Zimmermann H, Vorkauf H, Sentinella Working Group. A national measles epidemic in Switzerland in 1997: Consequences for the elimination of measles by the year 1997. Eurosurveillance 2000; 5: 17–22.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Epidemiology and Infectious Diseases, Swiss Federal Office of Public Health, Berne, Switzerland

    Jean-Luc Richard, Mirjam Feuz & Hans C. Matter

  2. Department of Social and Preventive Medicine, University of Berne, Switzerland

    Marcel Zwahlen

Authors
  1. Jean-Luc Richard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcel Zwahlen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mirjam Feuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hans C. Matter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richard, JL., Zwahlen, M., Feuz, M. et al. Comparison of the effectiveness of two mumps vaccines during an outbreak in Switzerland in 1999 and 2000: A case–cohort study. Eur J Epidemiol 18, 569–577 (2003). https://doi.org/10.1023/A:1024698900332

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1024698900332

Search

Navigation